J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.
Z. S. Pavletic,Michael R. Bishop,Stefano R. Tarantolo,S. Martin-Algarra,P. J. Bierman,Julie M. Vose,Elizabeth C. Reed,Thomas G. Gross,Jeffrey P. Kollath,K. Nasrati,John D. Jackson,James O. Armitage,Anne Kessinger +12 more
TL;DR: In comparison to BMT, allogeneic BSC transplantation may result in faster hematopoietic recovery, shorter hospital stay, and similar early survival, and whether allogeneIC BSC are superior to bone marrow needs to be determined in randomized trials.
Journal ArticleDOI
Non-Hodgkin's lymphomas, version 4.2014
Andrew D. Zelenetz,Leo I. Gordon,William G. Wierda,Jeremy S. Abramson,Ranjana H. Advani,C. Babis Andreadis,Nancy L. Bartlett,John C. Byrd,Myron S. Czuczman,Luis Fayad,Richard I. Fisher,Martha Glenn,Nancy L. Harris,Richard T. Hoppe,Steven M. Horwitz,Chris R. Kelsey,Youn H. Kim,Susan Krivacic,Ann S. LaCasce,Auayporn Nademanee,Pierluigi Porcu,Oliver W. Press,Rachel Rabinovitch,Nishitha Reddy,Erin Reid,Ayman Saad,Lubomir Sokol,Lode J. Swinnen,Christina Tsien,Julie M. Vose,Joachim Yahalom,Nadeem Zafar,Mary A. Dwyer,Hema Sundar +33 more
TL;DR: Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR for patients presenting with advanced-stage disease.
Journal ArticleDOI
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Anas Younes,Julie M. Vose,Andrew D. Zelenetz,Mitchell R. Smith,Howard A. Burris,Stephen M. Ansell,Jerry Klein,W. Halpern,W. Halpern,R. Miceli,Elizabeth Kumm,N. L. Fox,Myron S. Czuczman +12 more
TL;DR: Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in patients with FL, and was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity.
Journal ArticleDOI
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma.
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Wing C. Chan,Patricia Aoun,Gregory T. Cochran,Zenggang Pan,Lynette M. Smith,James C. Lynch,Robert G. Bociek,Philip J. Bierman,Julie M. Vose,James O. Armitage +12 more
TL;DR: Cyclin D2 and PKC-β expression will be useful in designing a ‘biological prognostic index’ for patients with DLBCL.
Journal ArticleDOI
Angioimmunoblastic T-cell lymphoma: the many faced lymphoma
Matthew A. Lunning,Julie M. Vose +1 more
TL;DR: Induction strategies continue to focus on increasing complete remission rates that allow more transplant-eligible patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with improving long-term survival.